A detailed history of Swiss National Bank transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Swiss National Bank holds 134,700 shares of TVTX stock, worth $2.56 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
134,700
Previous 134,700 -0.0%
Holding current value
$2.56 Million
Previous $1.11 Million 70.19%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 08, 2024

SELL
$5.26 - $8.28 $67,854 - $106,811
-12,900 Reduced 8.74%
134,700 $1.11 Million
Q3 2023

Nov 08, 2023

BUY
$7.64 - $17.25 $74,108 - $167,325
9,700 Added 7.03%
147,600 $1.32 Million
Q2 2023

Aug 09, 2023

SELL
$15.3 - $22.61 $42,840 - $63,308
-2,800 Reduced 1.99%
137,900 $2.12 Million
Q1 2023

May 10, 2023

BUY
$17.82 - $22.89 $167,508 - $215,166
9,400 Added 7.16%
140,700 $3.16 Million
Q4 2022

Feb 08, 2023

BUY
$18.47 - $26.14 $60,950 - $86,262
3,300 Added 2.58%
131,300 $2.76 Million
Q3 2022

Nov 09, 2022

BUY
$22.91 - $28.63 $32,074 - $40,082
1,400 Added 1.11%
128,000 $3.15 Million
Q2 2022

Aug 09, 2022

SELL
$20.94 - $30.01 $77,478 - $111,037
-3,700 Reduced 2.84%
126,600 $3.07 Million
Q1 2022

May 09, 2022

BUY
$23.61 - $30.6 $238,461 - $309,060
10,100 Added 8.4%
130,300 $3.36 Million
Q3 2021

Nov 08, 2021

BUY
$12.98 - $25.03 $76,582 - $147,677
5,900 Added 5.16%
120,200 $2.92 Million
Q2 2021

Aug 06, 2021

SELL
$14.11 - $26.4 $59,262 - $110,880
-4,200 Reduced 3.54%
114,300 $1.67 Million
Q1 2021

May 07, 2021

BUY
$23.37 - $31.77 $483,759 - $657,639
20,700 Added 21.17%
118,500 $2.96 Million
Q4 2020

Feb 05, 2021

BUY
$19.17 - $27.87 $1.87 Million - $2.73 Million
97,800 New
97,800 $2.67 Million

Others Institutions Holding TVTX

About Travere Therapeutics, Inc.


  • Ticker TVTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 64,173,600
  • Market Cap $1.22B
  • Description
  • Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...
More about TVTX
Track This Portfolio

Track Swiss National Bank Portfolio

Follow Swiss National Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Swiss National Bank with notifications on news.